GLP-1 ad war spills into court as Novo Nordisk alleges Eli Lilly ignores science

Ubiquitous TV advertisements for weight-loss drugs are the focus of a new legal dispute between heavyweight pharmaceutical rivals. Novo Nordisk, the maker of the GLP-1 medication Wegovy, filed a lawsuit Tuesday alleging Eli Lilly’s spots deceptively claim Wegovy is considerably weaker than Zepbound...

Redirecting to full article...